Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 6, 2011, Pages 581-588

  Moore, Kenneth Todd ^a   Plotnikov, Alexei Nikolaevich ^b   Thyssen, An ^c   Vaccaro, Nicole ^b   Ariyawansa, Jay ^b   Burton, Paul Bryan ^b  

^a JOHNSON AND JOHNSON   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

clopidogrel adverse effects; drug tolerance; omeprazole pharmacology; rivaroxaban pharmacokinetics; rivaroxaban pharmacology

Indexed keywords

OMEPRAZOLE; PARACETAMOL; RIVAROXABAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHARMACOKINETICS; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; TIME TO LAST QUANTIFIABLE PLASMA CONCENTRATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN;

ADOLESCENT; ADULT; ANTICOAGULANTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FACTOR XA; FEMALE; HUMANS; MALE; MORPHOLINES; OMEPRAZOLE; PROTON PUMP INHIBITORS; THIOPHENES; YOUNG ADULT;

EID: 83155181625     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31822f6c2b     Document Type: Article

References (44)

1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31: 2369-2429.
2. Singer DE, Albers GW, Dalen JE, et al. American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:546S-592S. (Pubitemid 351892972)
3. Eikelboom J, Guyatt G, Hirsh J. Guidelines for anticoagulant use in acute coronary syndromes. Lancet. 2008;371:1559-1561. (Pubitemid 351635926)
4. Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
5. Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials. Lancet. 2009;374:989-997.
6. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118:1894-1909.
7. Moukarbel GV, Signorovitch JE, Pfeffer MA, et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: The VALIANT Trial. Eur Heart J. 2009;30:2226-2232.
8. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033-2038. (Pubitemid 34680594)
9. Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: A nationwide cohort study. Ann Intern Med. 2010;153: 378-386.
10. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101: 714-719.
11. Bristol-Myers Squibb. Pfizer. APPRAISE-2 study with investigational compound apixaban in acute coronary syndrome discontinued. 2010. Available at: Http://www.businesswire.com/news/home/20101118007161/ en/APPRAISE-2-Study- Investigational-Compound-Apixaban-Acute- Coronary. Accessed March 30, 2011.
12. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. (Pubitemid 38955611)
13. Gurbel PA, Tantry US. Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy. Nat Rev Cardiol. 2011;8:7-8.
14. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-718.
15. Medical News TODAY. PRADAX (dabigatran etexilate) gains approval in Canada for stroke prevention in atrial fibrillation. 2010. Available at: Http://www.medicalnewstoday.com/printerfrien lynews.php? newsid=205933. Accessed January 11, 2010.
16. Ageno W. Recent advances in the management of venous thromboembolism. Korean J Hematol. 2010;45:8-13.
17. ClinicalTrials.gov. RE-DEEM dose finding study for dabigatran etexilate in patients with acute coronary syndrome. 2010. Available at: Http://clinicaltrials.gov/ct2/show/NCT00621855. Accessed December 14, 2010.
18. Boehringer Ingelheim. Dabigatran FDA Advisory Committee Briefing Document. 2010. Available at: Http://www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenal DrugsAdvisoryCommittee/UCM226009.pdf. Accessed December 14, 2010.
19. Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa (dabigatran etexilate mesylate) Prescribing information. 2010. Available at: Http://bidocs. boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa. pdf. Accessed December 13, 2010.
20. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
21. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363: 2499-2510.
22. Patel MR, Mahaffey KW, Garg J. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibillation. N Engl J Med. 2011 Aug 10 [Epub ahead of print].
23. Mega JL, Braunwald E, Mohanavelu S, et al. Atlas ACS-TIMI 46 Study Group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet. 2009;374:29-38.
24. ClinicalTrials.gov. An efficacy and safety study for rivaroxaban in patients with acute coronary syndrome. 2011. Available at: Http:// clinicaltrials. gov/ct2/show/NCT00809965. Accessed March 30, 2011.
25. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412-421. (Pubitemid 41393676)
26. Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47:218-226. (Pubitemid 46146488)
27. Kubitza D, Becka M, Roth A, et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008;24:2757-2765.
28. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008; 47:203-216.
29. Bayer HealthCare AG. Rivaroxaban FDA Advisory Committee Briefing Document. 2011. Available at: Http://www.fda.gov/ohrms/dockets/ ac/09/briefing/2009-4418b1-01-FDA.pdf. Accessed January 6, 2011.
30. Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46:549-558.
31. AstraZeneca. Losec (omeprazole): summary of product characteristics. 2008. Available at: Http://www.medicines.org.uk/emc/medicine/16009. Accessed March 14, 2011.
32. Smith SA, Morrissey JH. Thromboplastin composition affects the sensitivity of prothrombin time (PT) clotting tests to direct Factor Xa inhibitors (ASH Annual Meeting Abstracts). Blood. 2007;110. Abstract 928.
33. Wo JM, Eversmann J, Mann S. Pharmacokinetic profile of immediate- release omeprazole in patients with gastro-oesophageal reflux associated with gastroparesis. Aliment Pharmacol Ther. 2010;31: 516-522.
34. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor -after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873-880. (Pubitemid 41803696)
35. Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther. 2007;45: 335-344. (Pubitemid 46895052)
36. Dunn SP, Macaulay TE, Brennan DM. Baseline proton pump inhibitor use associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation. 2008;118:S815.Abstract 3999.
37. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301: 937-944.
38. Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: Results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry. Circulation. 2011;123: 474-482.
39. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363: 1909-1917.
40. Southworth MR, Temple R. Interaction of clopidogrel and omeprazole. N Engl J Med. 2010;363:1977.
41. Banerjee S, Weideman RA, Weideman MW, et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol. 2011;107:871-878.
42. Kato H, Ishii T, Akimoto T, et al. Prevalence of linked angina and gastroesophageal reflux disease in general practice. World J Gastroenterol.2009;15:1764-1768.
43. Kubitza D, Becka M, Mueck W, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct Factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol. 2006;46: 981-990. (Pubitemid 44215062)
44. Kubitza D, Becka M, MueckW, et al. Co-administration of rivaroxaban- a novel, oral, direct Factor Xa inhibitor-and clopidogrel in healthy subjects. Eur Heart J. 2007;28(suppl 1):189. Abstract P1272.